News & Updates

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.

Although the COVID-19 pandemic is over, the disease remains a threat as it is predicted to become a significant danger to public health in the next 2 years, particularly in the US, according to a study. Wide-ranging vaccination, however, can counter this potential problem.